Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • IRAK1/4
      • RIPK1
      • COVID-19
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Oct 02, 2008 7:30am EDT

Rigel to Present at JMP Securities Healthcare Focused Conference

Aug 27, 2008 7:30am EDT

Rigel to Present at Thomas Weisel Partners Healthcare Conference

Jul 03, 2008 7:30am EDT

Rigel to Present at Collins Stewart Growth Conference

Jun 18, 2008 7:30am EDT

Rigel to Present at Jefferies Healthcare Conference

Jun 12, 2008 7:30am EDT

Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis

Jun 05, 2008 7:30am EDT

Rigel to Present at the Needham Biotechnology and Medical Technology Conference

Jun 03, 2008 6:00am EDT

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

Jun 02, 2008 5:10pm EDT

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

May 06, 2008 7:30am EDT

Rigel Announces First Quarter 2008 Financial Results

Mar 27, 2008 7:30am EDT

Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference

  • Previous
  • 1…
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin